MAPT and Alzheimer disease: A simple definition of preclinical AD by the International panel (IWG-2014): No clinical symptoms of AD but positive AD biomarker values (in CSF: decreased Aβ42, increased tau and/or p-tau in CSF; or in brain imaging: increased fibrillary amyloid on PET; Dubois et al., 2014).